^
    1d
    Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature. (PubMed, Haematologica)
    Not available.
    Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    Calquence (acalabrutinib)
    1d
    Bullous Wells' Syndrome: Case Report and Systematic Review. (PubMed, J Clin Med)
    Recent studies described the efficacy of the anti-interleukin-5 monoclonal antibody Mepolizumab in refractory cases of WS...Integrating clinical features with laboratory and histopathological findings is essential for achieving a definitive diagnosis. Although the causal link between WS and underlying neoplastic/autoimmune/infective conditions is not always present, this possibility should be taken into account and investigated for the best patient management.
    Review • Journal
    |
    IL5 (Interleukin 5)
    1d
    Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date
    |
    Gomekli (mirdametinib)
    1d
    CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Jul 2026
    Trial completion date
    |
    Triplex (CMV-MVA vaccine)
    2d
    Functional differences between CLL- and ALL-derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL-10 as potential modulatory targets. (PubMed, Hemasphere)
    Importantly, combining CAR T-cell treatment with interleukin-10 (IL-10) or CXCR4 blockade effectively improved cytotoxicity against CLL cells, even in stromal-protected regions within the 3D model. These findings offer insights into CAR T-cell dysfunction in CLL and support novel TME-targeted combination strategies to improve clinical outcomes.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • IL10 (Interleukin 10)
    3d
    REL overexpression and sustained NF-κB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia. (PubMed, Leukemia)
    Moreover, upon ibrutinib treatment, REL DNA-binding activity decreased in 2pWT CLL cells but remained sustained in 2p+ CLL cells following BCR stimulation, suggesting that persistent NF-κB activation contributes to resistance...Altogether, our study identifies REL overexpression as a novel 2p+-driven mechanism of BTKi resistance in CLL, complementing the well described BTK and PLCG2 mutations. These findings support the clinical relevance of detecting 2p gain to guide treatment strategies and improve outcomes in CLL.
    Journal
    |
    PLCG2 (Phospholipase C Gamma 2) • REL (REL Proto-Oncogene)
    |
    Imbruvica (ibrutinib)
    3d
    A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies (clinicaltrials.gov)
    P2, N=108, Not yet recruiting, Curis, Inc.
    New P2 trial
    |
    Brukinsa (zanubrutinib) • emavusertib (CA-4948)
    3d
    REBELLE: Determinants of the Response to BTK Degraders (BTKd) in Double Refractory CLL (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2025 --> Sep 2039
    Enrollment open • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    3d
    BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (PubMed, J Clin Oncol)
    Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.
    P3 data • Journal • IO biomarker
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Rituxan (rituximab) • Jaypirca (pirtobrutinib) • bendamustine
    4d
    Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, University of Alabama at Birmingham | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    4d
    P17-132: Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, AbbVie | Active, not recruiting --> Recruiting | N=350 --> 500 | Trial completion date: Dec 2025 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2030
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • Chr del(17p) • TP53 mutation + Chr del(17p)
    |
    Venclexta (venetoclax)
    4d
    POSBIO-CRC: Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery (clinicaltrials.gov)
    P=N/A, N=164, Recruiting, AC Camargo Cancer Center
    New trial